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Meeting report: human breast cancer genetics
The 23rd Paterson Symposium was held from 23 to 26
October at the Paterson Institute for Cancer Research
(Cancer Research Campaign), Manchester, UK. This year's
topic was Human Breast Cancer Genetics and the meeting
was attended by an international group of about 40 scientists
in the forefront of this field, over 20 of whom were also
speakers.
The aim was to cover three main topics: first to review the
evidence for heritable predisposition to breast cancer,
secondly to examine the genetic changes which take place
during the initiation and progression of breast tumours and,
finally, to return to the theme of genetic predisposition and
consider possible methods of detection and counselling of
women at risk.
The first session was introduced by D.E. Anderson (Texas,
USA) with an overview of familial and genetic pre-
disposition. The familial occurrence of breast cancer has
been studied for over 50 years and a 2-3-fold excess risk has
consistently been observed in mothers, sisters and daughters
of index cases compared with age-matched controls. The
excess risk increases when the index case is young at
diagnosis or has bilateral disease, reaching a value of about
9-fold in sisters of early onset, bilateral cases. Refinements to
risk estimates for first degree relatives in relation to age of
patients and relatives were given by J. Peto and D.F. Easton
(Oxford, UK) from a population based cohort study of
1,454 index cases, utilising the records of the Office of
Populations Censuses and Surveys. A relative risk of only
1.7 was found for relatives of patients whose cancer was
diagnosed over the age of 50.
Familial clustering does not of course automatically
indicate heritability; shared environmental effects and
culturally associated risk factors are other possibilities.
However, some dramatic multiple-case families are known
(M.-C. King, California, USA; J. MacKay, Edinburgh, UK)
in which heritable predisposition is strongly indicated. M.-C.
King described a complex segregation analysis of 1,579
nuclear families of index cases diagnosed before the age of
55 (see Newman et al., 1988). The data were consistent with
an autosomal dominant mode of inheritance, with a lifetime
penetrance of 82%, in 4% of families. Hypotheses of no
heritable transmission or of multifactorial inheritance
without the influence of a major gene were rejected. The
model was also consistent with the pattern of disease
clustering seen in an extended kindred at high risk of breast
cancer.
In those rare families exhibiting hereditary breast cancer,
the tumours may be site-specific or may be associated, in
some families, with an excess of other cancers. J.M. Birch
(Manchester, UK) in a population-based study of families
with the Li-Fraumeni syndrome (breast cancer in association
with childhood soft tissue sarcomas) has detected an excess
risk of various cancers among first degree relatives of the
children with soft tissue sarcomas. For all mothers, the
average relative risk of breast cancer was 3, but was much
higher in mothers of children with embryonal rhabdomyo-
sarcomas diagnosed at a particularly early age. Birch argued
that cytogenetic and restriction fragment length poly-
morphism (RFLP) analyses of tumours are consistent with
the pleiotropic expression of a gene on chromosome ipiS
leading to childhood embryonal tumours, breast cancers and
other Li-Fraumeni syndrome cancers.
Boyle (Lyon, France) discussed the many non-genetic
factors which have been claimed to alter the risk of breast
cancer, including parity, age at first birth, breast feeding,
oral contraception and diet. Changes in risk associated with
these factors are small, generally in the order of 1.5-2.0, and
required very large samples for detection. Consequently it
will be difficult to investigate the effect of these
environmental factors on genetic susceptibility.
The second session was devoted to tumour genetics and is
closely linked to the first topic because of increasing evidence
that genes involved in predisposition may, in some cases, be
the same as those involved in genetic changes within tumour
cells, as exemplified by retinoblastoma (Cavenee et al., 1983)
and colon cancer (Bodmer et al., 1987). This supports
Knudson's original 2-hit hypothesis (Knudson, 1971) that
the initiation of sporadic tumours requires mutation or
deletion of both alleles of a particular 'tumour suppressor
gene' whereas in predisposed individuals the first event is
inherited. Thus, although inheritance of predisposition
appears to be dominant, it is recessive at the cellular level.
The chromosomal location of a number of genes involved in
tumorigenesis has been suggested through detection of
specific deletion events in tumours (Cavenee et al., 1983;
Koufos et al., 1984; Seizinger et al., 1986). This rationale has
been applied to breast tumours and deletions have been
detected with cytogenic methods or through loss of hetero-
zygosity for RFLPs.
Mitelman (Lund, Sweden) pointed out some major
difficulties in detecting relevant specific cytogenetic changes
in breast tumours. Only a small proportion of tumours yield
mitoses which are analysable, so there is considerable
potential for bias, and in the karyotyped samples there is
often extreme numerical and structural complexity with
many unidentifiable chromosomes. Initiating primary
changes, if they exist, may be swamped by secondary
changes associated with tumour progression. These
possibilities must be recognised in attempting to attribute an
initiating role to the non-random involvement of
chromosomes lp(lpll-21), lq(12-23), 3p, 6q, Ilp,
1lq(1 lql3-24), 13q and 16q in structural aberrations,
including deletions.
RFLP studies have detected non-random deletion events
of certain chromosome regions, notably 1 p (Ali et al., 1988)
and chromosome 13 (C. Larsson, Stockholm; see Lundberg
et al., 1987). J. MacKay (Edinburgh, UK) found loss of
heterozygosity for polymorphic loci on llp in 39% (19/49)
of cases, using up to five probes. Further investigations did
not, however, reveal a single deleted region common to all
cases but suggested rather complex rearrangements involving
lip. Using just one lip probe (c-Ha-ras) in 100 tumours,
MacKay observed allele loss in 22% of informative cases
(14/65) which was correlated with paucity of oestrogen
receptor protein and with increased tumour size at presen-
tation. With the highly polymorphic probe YNZ22 (chromo-
some 17pl3.3) he found 61% (23/38) loss of heterozygosity
but this was not related to prognostic factors. This high level
of 17p deletion is a striking contrast to the cytogenetic
observations which have not revealed an unusual involve-
ment of chromosome 17. The deletion may be too small for
cytogenetic detection, may be associated with duplication of
the non-deleted homologue or with somatic recombination,
or the tumours on which cytogenetic data have been
obtained may be non-representative, as Mitelman warned.
Genetic events other than allele loss appear to be involved
in breast cancer and there have been many reports of over-
expression, amplification and rearrangements of proto-
oncogenes. Current interest centres on c-erbB-2 (or neu)
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which is amplified in 10-40% (depending upon the study) of
tumours. There were several presentations relating amplifica-
tion and expression of c-erbB-2 to prognosis.
W.J. Gullick (London, UK) described the use of anti-
bodies directed against the c-erbB-2 protein in three colla-
borative immunohistochemical studies comprising a total of
approximately 500 patients. All the studies suggested that
positive staining for c-erbB-2 was correlated with poor
prognosis and in one of the investigations the correlation
was highly significant. On the same theme N.E. Hynes
(Berne, Switzerland) reported a correlation between immuno-
histochemical detection of c-erbB-2 protein and both axillary
lymph node involvement and tumour nuclear grade. How-
ever, in a study of expression of the gene in primary
tumours, in 79 node negative breast cancer patients the
presence of the marker was not a statistically significant
predictor of relapse unless combined with oestrogen receptor
status. A similar study from J. Nusse (Amsterdam, The
Netherlands) looked at the correlation between c-erbB-2 gene
amplification and expression. Intense membrane staining was
detected using monoclonal antibodies in 10/10 tumours with
gene amplification but only 2/28 tumours with an apparently
normal gene copy number. A larger study suggested that c-
erbB-2 expression was correlated with increased tumour size
and poor histological grade. An interesting observation was
the demonstration of positive c-erbB-2 staining in 17/42
ductal carcinomas in situ, all being of the large cell comedo
type. This may suggest an early role for over-expression of
the gene in the development of a distinct histological sub-
type of breast cancer. R.A. Walker (Leicester, UK) reported
a good correlation between c-erbB-2 amplification and detec-
tion of the protein product (immunochemistry) or of mRNA
by in situ hybridisation; again the increased expression
indicated poor prognosis, particularly for cases with lymph
node metastases and poor differentiation of the primary
carcinomas.
Alterations to other proto-oncogenes in tumours received
less attention, although G. Peters (London, UK) reported
studies of int-2, which is adjacent to the integration site for
mammary tumour virus in mice. The human homologue of
int-2 is located at llql3 and was found to be amplified in
20/106 primary breast tumours but this did not appear to
correlate with expression. Other markers in this region also
showed amplification, but not as frequently, and it was
suggested that another unidentified gene 5' to int-2 may be
important in the molecular events linked to the development
of breast cancer.
The final session was devoted to possible methods of
detection of individuals at increased risk through genetic
predisposition. A. Howell (Manchester, UK) argued the need
to identify high risk groups because general population
screening by mammography is 'a blunt tool'; the potential
for over-diagnosis is enormous in that in only one of four
women diagnosed with in situ lesions is there likely to be
progression to an invasive malignancy. Several studies have
found that in about 50% of women with breast cancer,
multicentric and bilateral in situ lesions may be found.
Howell argued that these may be the cases with genetic
predisposition but acknowledged that this figure is an order
of magnitude greater than that derived from segregation
analysis of the type presented earlier by M.-C. King.
Potentially, genetic predisposition can be detected if the
predisposing gene itself, or a closely linked polymorphic
locus, is identified and can be used as a marker. M.-C. King
described tests of genetic linkage of breast cancer to several
loci in extended families with at least three living affected
members. No close linkage was found to nine proto-
oncogenes, most of which have been implicated in breast
cancer from other studies, i.e. H-ras (1lplS.5), K-ras
(12pl2.1), N-ras (lp22 or p13), c-myc (8q24), c-myb (6q22-
q23), c-erbA2 (17q21), int-2 (1lql3) and rafl (3p25). These
results strongly suggest that these oncogenes are not the sites
of primary lesions for inherited breast cancer, which is
consistent with the hypothesis that primary carcinogenic
lesions are recessive alterations of tumour suppressor genes.
Alterations in proto-oncogenes may be more closely asso-
ciated with tumour progression. The results also exclude
certain chromosome regions in close proximity to these
markers as being the sites of predisposing genes. In particu-
lar, by using the probe for the insulin locus on lIp, in
addition to the H-ras probe, regions of lip associated with
loss of heterozygosity in tumours were excluded. Allele loss
in tumours is not always, therefore, indicative of the location
of inherited predisposing genes. However, in contrast to this
observation was the demonstration by MacKay that, having
detected a 61% allele loss at l7p13.3 in tumours, the same
probe used in linkage studies in a two generation family with
seven affected members gave a suggestive positive lod score
of 1.6.
The alternative strategy to identifying predisposing genes
or closely linked DNA sequences for detecting individuals at
risk is to identify other cellular characteristics which are
strongly associated with heritable cancer-proneness. S.L.
Schor (Manchester, UK; see Schor et al., 1987) has detected
abnormal (fetal like) migratory behaviour of skin fibroblasts
in 90% premenopausal patients with familial breast cancer,
in 65% of unaffected first degree relatives and in less than
10% of normal healthy controls. However, cells from 50%
of patients with sporadic breast cancer also behaved in this
way. Again, if we accept that less than 5% of cases are
genetically predisposed this 'marker' may be detecting pre-
disposition, but not heritable predisposition. Perhaps the
50% are those women with multifocal disease (see Howell,
above). Similar findings were reported by N.G. Testa (Man-
chester, UK) who observed that in 68% (55/81) of patients
with a family history of breast cancer, peripheral blood
monocytes formed multinucleated cells in vitro (see Al-
Sumidaie et al., 1988). Values of 63% (15/24) were found in
first degree relatives and 27% (13/47) in normal controls.
However, there was no significant difference between
patients with or without a family history.
Hypersensitivity to the induction of chromosome damage
by ionising radiation has been observed in a number of
heritable cancer-prone syndromes, notably ataxia-
telangiectasia and Fanconi's anaemia (Taylor, 1983). D.
Scott (Manchester, UK) reported investigations of chromo-
somal radiosensitivity in various phases of the cell cycle in
peripheral blood lymphocytes of index cases in families with
a frequency and pattern of breast cancers suggestive of
heritable predisposition, in first degree relatives and in
sporadic breast cancers. None of these groups showed a
sensitivity greater than in normal healthy controls.
At present there is no reliable phenotypic marker of
predisposition. B.H.A. Ponder (London, UK) pointed out
the potential value of such a marker in identifying women
who are not at risk. To predict high risk, the marker must
indicate not only that the individual is a gene carrier but the
likely expression of the gene as well.
Having accepted that there is a degree of heritable pre-
disposition to breast cancer there is a need to provide advice
to families who may be at increased risk. Ponder described
his experiences in counselling such families. The essence of
genetic counselling is to define the risks and to advise on
appropriate action. Risks for breast cancer are difficult to
define and have to be based on an averaging of risk
estimates which assume that an individual is from a family
of gene carriers and estimates based upon empirical or
population data, taking into account the number of affected
individuals within a family and the age of onset. Even for
gene carriers the penetrance for a particular individual is
unknown (although average lifetime penetrance could be
high, see M.-C. King above) and may depend upon genetic
factors (independently assorting modifying genes) and/or
environmental influences such as parity, age at first birth
and lifestyle. Having made an estimate of risk, however
crude, the options presented include doing nothing in low656 HUMAN BREAST CANCER GENETICS
risk cases, advising self-examination and possible changes in
lifestyle, regular screening and, in the extreme, prophylactic
mastectomy. Chemoprevention by e.g. tamoxifen treatment
is a possibility for the future. An assessment should be made
of the costs and benefits of mammography in young women
with a family history of breast cancer.
The mood of the meeting was one of enthusiasm and
optimism with a clear recognition of significant recent
developments, particularly in the application of recombinant
DNA techniques. There were predictions that linkage studies
would locate predisposing genes within two years but a
caution that the disease is heterogeneous and several differ-
ent genes may be involved. Identification of such genes
should lead to a much clearer understanding of the nature of
this common disease and to improvements in detection,
prevention and treatment.
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